Aurobindo Pharma Limited

NSE:AUROPHARMA.NS

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Chemicals & Advanced Materials

🔬 Clinical Trials

Location

India

Market Cap

USD 7.63 B

Share Price

USD 13.11

Avg Daily Volume

1,293,153

Change (1 day)

0.06%

Change (1 year)

-7.85%

Change (YTD)

-15.88%

Aurobindo Pharma Limited Shareholders' Equity for the year ending March 31, 2025: USD 3.82 B

Aurobindo Pharma Limited Shareholders' Equity is USD 3.82 B for the year ending March 31, 2025, a 6.80% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Aurobindo Pharma Limited Shareholders' Equity for the year ending March 31, 2024 was USD 3.58 B, a 9.56% change year over year.
Aurobindo Pharma Limited Shareholders' Equity for the year ending March 31, 2023 was USD 3.27 B, a 0.89% change year over year.
Aurobindo Pharma Limited Shareholders' Equity for the year ending March 31, 2022 was USD 3.24 B, a 8.07% change year over year.
Aurobindo Pharma Limited Shareholders' Equity for the year ending March 31, 2021 was USD 2.99 B, a 34.14% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Shareholders' Equity	Cash and Short-Term Investments	Receivables	Inventory

NSE: AUROPHARMA.NS

Aurobindo Pharma Limited

CEO	Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.
IPO Date	Jan. 15, 1996
Location	India
Headquarters	Galaxy, Plot No. 1
Employees	26,015
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Chemicals & Advanced Materials 🔬 Clinical Trials

Description

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.